70 likes | 189 Vues
E.J. Soini et al. Current Medical Research & Opinion 2010;26:25-36. Model’s flow-chart. E.J. Soini et al. Current Medical Research & Opinion 2010;26:25-36. Drugs (excluding VAT), resources, and CHD-related morbidity management (state costs).
E N D
E.J. Soini et al. Current Medical Research & Opinion 2010;26:25-36
Model’s flow-chart E.J. Soini et al. Current Medical Research & Opinion 2010;26:25-36
Drugs (excluding VAT), resources, and CHD-related morbidity management (state costs) E.J. Soini et al. Current Medical Research & Opinion 2010;26:25-36
Non-fatal and fatal event costs (gamma distribution assumed in the probabilistic analysis) E.J. Soini et al. Current Medical Research & Opinion 2010;26:25-36
Base-case results E.J. Soini et al. Current Medical Research & Opinion 2010;26:25-36
Cost-effectiveness acceptability frontier (CEAF) for men (a) and women (b) without and with diabetes using generic S40 (dashed black line) or S40+EZ10 E.J. Soini et al. Current Medical Research & Opinion 2010;26:25-36
Incremental cost-effectiveness ratios (ICER) as the function of baseline LDL-C and most cost-effective medications E.J. Soini et al. Current Medical Research & Opinion 2010;26:25-36